Gerald Appel, MD
Nephrology · New York, NYNPI 1306918651
Payments from drug & device makers
Across 687 payments — averaging $2122.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$367K
- Sanofi$322K
- GSK$167K
- Aurinia Pharma U.S., Inc.$142K
- AstraZeneca$142K
- Genentech, Inc.$70K
- plus $248K from 14 others
Across 2 payments — averaging $718.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$1K
What the payments were for
- Consulting fees$107,88813%
- Speaking & faculty fees$621,56774%
- Travel & lodging$101,34312%
- Food & beverage$10,8971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 257 | $366,977 |
| Sanofi | 42 | $321,637 |
| GSK | 125 | $166,528 |
| Aurinia Pharma U.S., Inc. | 115 | $142,337 |
| AstraZeneca | 21 | $142,151 |
| Genentech, Inc. | 18 | $70,141 |
| Janssen Research & Development, LLC | 1 | $59,099 |
| EMD Serono, Inc. | 35 | $42,246 |
| Biogen | 1 | $32,137 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27,857 |
| Genentech USA, Inc. | 21 | $22,492 |
| Travere Therapeutics, Inc. | 26 | $21,754 |
| Vertex | 5 | $9,497 |
| Novartis | 6 | $9,307 |
| Biocryst Pharmaceuticals, Inc. | 4 | $7,950 |
| Roche Products Limited | 2 | $5,833 |
| Amgen | 2 | $5,125 |
| Pfizer | 2 | $3,000 |
| Eli Lilly | 1 | $1,650 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $158 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,457,875 in reported general payments places this provider in the 95th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Zolpidem Tartrate | 12 | $51 |
Paid to pharmacies, not to this prescriber.
Other nephrology in New York
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- David CharytanNew York$1.3M
- Kirk CampbellNew York$1.1M
- Jai RadhakrishnanNew York$995K
- Girish NadkarniNew York$978K
- David GoldfarbNew York$808K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.